Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty 100 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's reported Q1 FY26 consolidated revenue of ₹85,452 million, up 11% year-on-year but flat sequentially, driven by strong growth in Europe (up 142% on NRT portfolio contribution) and Emerging Markets (up 18%), partly offset by an 11% decline in North America due to pricing pressure on Lenalidomide. Gross margin contracted to 56.9% from 60.4% a year ago (down 350 bps), and EBITDA margin fell to 26.7% from 28.2% on higher price erosion and reduced operating leverage. Profit after tax attributable to equity holders rose 2% YoY to ₹14,178 million, though it declined 11% sequentially. Diluted EPS stood at ₹17.02. The company remained net cash positive with ₹29,220 million in net cash surplus and a Net Debt to Equity ratio of (0.08), generated free cash flow of ₹4,514 million, and delivered RoCE of 22%. Auditors S.R. Batliboi & Associates issued an unmodified limited review report.
Mixed quarter for shareholders — topline growth was healthy and balance sheet remains strong, but margin compression from US generics pricing pressure signals near-term profitability headwinds, which management flagged could intensify on Lenalidomide in the US market.